Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thiamine hydrochloride + methylnicotinate is a topical pharmaceutical combination used for the symptomatic relief of musculoskeletal pain, including myalgia, neuralgia, and joint pain. Methyl nicotinate acts as a rubefacient and potent vasodilator; upon topical application, it induces local hyperemia and a warming sensation that serves as a counter-irritant to alleviate deeper pain. Thiamine hydrochloride (Vitamin B1) is included to support local metabolic processes and nerve health. This combination is most notably marketed under the brand name Algipan in certain European markets, such as Italy, where it is indicated for various minor sports injuries and rheumatic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiamine hydrochloride + methylnicotinate.